Brian Cheng
Stock Analyst at JP Morgan
(2.99)
# 3,576
Out of 4,829 analysts
65
Total ratings
63.16%
Success rate
3.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Initiates: Overweight | $41 | $25.53 | +60.60% | 1 | May 2, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | n/a | $24.29 | - | 1 | Mar 27, 2025 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $22 → $15 | $7.04 | +113.22% | 3 | Mar 6, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $53 → $57 | $45.22 | +26.05% | 5 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $45 → $13 | $8.63 | +50.64% | 4 | Feb 28, 2025 | |
| BPMC Blueprint Medicines | Maintains: Overweight | $126 → $129 | $100.13 | +28.83% | 2 | Feb 4, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Underweight | n/a | $4.10 | - | 2 | Jan 30, 2025 | |
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $1.49 | - | 3 | Dec 16, 2024 | |
| ZYME Zymeworks | Upgrades: Overweight | $18 | $12.12 | +48.51% | 2 | Dec 16, 2024 | |
| XNCR Xencor | Maintains: Overweight | $27 → $28 | $8.91 | +214.25% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $46 | $14.50 | +217.24% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $2.18 | +1,417.24% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.57 | +282.17% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $7.94 | +202.27% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.38 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $5 | $0.36 | +1,301.74% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $1.18 | +577.97% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $11.00 | +36.36% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.43 | +3,158.09% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.30 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.68 | +782.61% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.33 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.11 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $7.86 | +154.45% | 2 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $11.65 | +629.61% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $10.42 | +101.63% | 1 | Aug 3, 2021 |
CG Oncology
May 2, 2025
Initiates: Overweight
Price Target: $41
Current: $25.53
Upside: +60.60%
Ascentage Pharma Group International
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $24.29
Upside: -
iTeos Therapeutics
Mar 6, 2025
Maintains: Overweight
Price Target: $22 → $15
Current: $7.04
Upside: +113.22%
Protagonist Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $45.22
Upside: +26.05%
Intellia Therapeutics
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $8.63
Upside: +50.64%
Blueprint Medicines
Feb 4, 2025
Maintains: Overweight
Price Target: $126 → $129
Current: $100.13
Upside: +28.83%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Underweight
Price Target: n/a
Current: $4.10
Upside: -
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.49
Upside: -
Zymeworks
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $12.12
Upside: +48.51%
Xencor
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $8.91
Upside: +214.25%
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $14.50
Upside: +217.24%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $2.18
Upside: +1,417.24%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.57
Upside: +282.17%
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $7.94
Upside: +202.27%
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.38
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $0.36
Upside: +1,301.74%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $1.18
Upside: +577.97%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $11.00
Upside: +36.36%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.43
Upside: +3,158.09%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $1.30
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.68
Upside: +782.61%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $3.33
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $1.11
Upside: -
Sep 2, 2021
Initiates: Overweight
Price Target: $20
Current: $7.86
Upside: +154.45%
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $11.65
Upside: +629.61%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $10.42
Upside: +101.63%